Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 101 results for "Tecfidera Treated Patients"

An Investing Overview of the Multiple Sclerosis Market
Motley Fool

An Investing Overview of the Multiple Sclerosis Market

Image source: . The market for multiple sclerosis drugs is worth $19 billion annually and treatment advances could lead to significant shifts in market share. Can market share Goliath Biogen ( NASDAQ:BIIB ) sidestep competitive risk? Or, will ... Motley Fool, 1 month ago
Medications for Multiple Sclerosis EverydayHealth.com, 2 months ago

1 images for "Tecfidera Treated Patients"

European Pharmaceutical Review, 4 months ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 7, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago

Key Pharma News Issue - Companies Target Ever Rarer Diseases with No Real Therapeutic Options and Patient Groups Become More Empowered - Research and Markets

Research and Markets has announced the addition of the "Key Pharma News Issue 50" report to their offering. Ownership Of Digital Reputation Crucial With Growing Compassionate Use Demand As companies target ever rarer diseases with no real ...
 4 Traders2 months ago Dynamics Within Industry-Academia Partnerships Changing - Research and Markets  Benzinga.com2 months ago
[x]  

Biogen pays $75M to Ionis on early PhIII antisense results

Biogen ($BIIB) has clocked a win on Phase III data for nusinersen to treat rare, severe genetic disease spinal muscular atrophy (SMA) with partner Ionis Pharmaceuticals ($IONS). The trial was unblinded early at an interim endpoint due to significant ...
 FierceBiotech3 weeks ago
FiercePharma

Biogen's top commercial exec leaves amid Tecfidera sales trouble

When a top biopharma executive abruptly shoves off, what comes next? Questions. Make that departing exec a sales-and-marketing chief, and couple that departure with slowing sales of a key product, and the questions multiply. Tony Kingsley That's ...
 FiercePharma1 month ago

Onset of Parkinson's Disease May Be Slowed by Metabolite in MS Drug, Mouse Study Shows

Dimethylfumarate (Tecfidera), a drug used to harness multiple sclerosis symptoms, generates a metabolite that could be used in Parkinson's patients to improve defenses against oxidative damage. The drug actson Nrf2, a molecule that has frequently ...
 Parkinson'sNewsToday.com2 months ago

5 Things a Neurologist Wants You to Know About Multiple Sclerosis

Scientists' understanding of MS is beginning to change as research on MS progression intensifies. Whether youre newly diagnosed with multiple sclerosis (MS) or have had it for decades, you probably have some questions about the disease, how it ...
 EverydayHealth.com2 weeks ago

Biotech targets Bayer growth hope Stivarga with IPR challenge

Bayer is counting on cancer med Stivarga to provide some serious growth going forward. But San Francisco's Fustibal has other plans. The biotech has filed a petition seeking an inter partes review of one of Bayer's Stivarga patents with the U.S.
 FiercePharma3 weeks ago
Motley Fool

Biogen not pursuing a sale: source

Home » Health » / no comments By Greg Roumeliotis (Reuters) U.S. biotechnology company Biogen Inc BIIB.O has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers, ...
 HealthMediciNet.com3 weeks ago Why Biogen Inc. Soared 18% in July  FOXBusiness.com3 weeks ago
Nasdaq

Takeover rumors juice Biogen stock, but fade fast

Dive Brief: Biogen stock jumped by over 9% in late trading Tuesday, spurred by reported takeover interest from Merck & Co. and Allergan. Shares rose to$330.11, a roughly $6 billion increase in market capitalization for the Cambridge, MA-based ...
 BioPharma Dive3 weeks ago Biogen CEO Scangos to Step Down -- WSJ  Nasdaq1 month ago Biogen : Announces CEO Search, Lifts Guidance--2nd Update  4 Traders1 month ago Biogen CEO to Step Down  Investors Hub1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less